MedTrace Logo

Innovative Therapeutic Treatments to Inhibit Perineural Invasion in Pancreatic Adenocarcinoma

NCT06616688 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-10-08

No results posted yet for this study

Summary

The overall goal of this project is to develop new therapeutic approaches to limit Perineural invasion (PNI) in pancreatic ductal adenocarcinoma (PDAC). PNI, has its higher incidence in PDAC, in which it is a recognized risk factor of poor survival. Considering the clinical relevance of PNI and its role in PDAC, it is urgent to identify molecular PNI signatures to develop new therapeutic strategies. We have recently identified a molecule that is activated in pancreatic cancer cells and initiate PNI. In this project we will hamper the signaling of this molecule in vitro, in human and murine organoids cocultured with myelinated Schwann cells neuronal cocultures, and in vivo in a mouse model faithfully reproducing human PNI. Thus, we will enroll patients undergoing surgical resection for PDAC, and a small piece of the resected tissue, performed for normal clinical practice after pathology evaluation, will be used to develop organoids.

This project is designed as an observational multicentric, transversal study. San Raffaele Hospital (OSR) is the only center enrolling patients.

The main goal of this Aim is to validate the effectiveness of NP-loaded hydrogel-based developed by CNR Nanotec Lecce, in vitro in organoids, which represent a suitable system to study PDAC.

Conditions

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

OTHER

Organoid-guided treatment

After specimen removal as per clinical practice and pathological examination, a small piece of tumor tissue will be sent to the Axo-Glial Interaction Unit and cultured to build up organoid cultures

Sponsors & Collaborators

  • National Nanotechnology Center (NANOTEC), The National Science and Technology Development Agency (NSTDA)

    collaborator UNKNOWN

  • IRCCS San Raffaele

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2026-12-31
Completion
2026-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06616688 on ClinicalTrials.gov